Compile Data Set for Download or QSAR
Report error Found 85 Enz. Inhib. hit(s) with all data for entry = 10288
TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525281(US11173137, Compound FA44 | US11173137, Compound A...)
Affinity DataIC50: 2nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525299(US11173137, Compound AK3-238)
Affinity DataIC50: 120nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525279(US11173137, Compound FA26 | US11173137, Compound ...)
Affinity DataIC50: 200nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525314(US11173137, Compound MCFA)
Affinity DataIC50: 300nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525281(US11173137, Compound FA44 | US11173137, Compound A...)
Affinity DataIC50: 620nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525290(US11173137, Compound FA35 | US11173137, Compound A...)
Affinity DataIC50: 700nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525303(US11173137, Compound AK3-261)
Affinity DataIC50: 1.16E+3nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525310(US11173137, Compound EEGI-055)
Affinity DataIC50: 1.20E+3nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525290(US11173137, Compound FA35 | US11173137, Compound A...)
Affinity DataIC50: 1.79E+3nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525280(US11173137, Compound AK3-99A)
Affinity DataIC50: 2.04E+3nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525281(US11173137, Compound FA44 | US11173137, Compound A...)
Affinity DataIC50: 2.98E+3nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M3(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525281(US11173137, Compound FA44 | US11173137, Compound A...)
Affinity DataKi:  3.00E+3nMAssay Description:Two exemplary compounds, FA44 and FA26, were screened against a panel of CNS receptors, transporters, and ion channels to examine specificity for CLC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetAlpha-2A adrenergic receptor(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525279(US11173137, Compound FA26 | US11173137, Compound ...)
Affinity DataKi:  3.00E+3nMAssay Description:Two exemplary compounds, FA44 and FA26, were screened against a panel of CNS receptors, transporters, and ion channels to examine specificity for CLC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525285(US11173137, Compound AK3-102A)
Affinity DataIC50: 3.60E+3nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M4(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525281(US11173137, Compound FA44 | US11173137, Compound A...)
Affinity DataKi:  5.00E+3nMAssay Description:Two exemplary compounds, FA44 and FA26, were screened against a panel of CNS receptors, transporters, and ion channels to examine specificity for CLC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525284(US11173137, Compound AK3-101B)
Affinity DataIC50: 5.29E+3nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525271(US11173137, Compound AK2-289B)
Affinity DataIC50: 7.16E+3nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525313(US11173137, Compound EEGI-060)
Affinity DataIC50: 7.32E+3nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525273(US11173137, Compound AK2-292)
Affinity DataIC50: 7.69E+3nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525309(US11173137, Compound EEGI-054)
Affinity DataIC50: 7.93E+3nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride intracellular channel protein 1(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525314(US11173137, Compound MCFA)
Affinity DataIC50: 9.00E+3nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525270(US11173137, Compound AK2-289A)
Affinity DataIC50: 9.86E+3nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M3(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525279(US11173137, Compound FA26 | US11173137, Compound ...)
Affinity DataKi: >1.00E+4nMAssay Description:Two exemplary compounds, FA44 and FA26, were screened against a panel of CNS receptors, transporters, and ion channels to examine specificity for CLC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525279(US11173137, Compound FA26 | US11173137, Compound ...)
Affinity DataKi: >1.00E+4nMAssay Description:Two exemplary compounds, FA44 and FA26, were screened against a panel of CNS receptors, transporters, and ion channels to examine specificity for CLC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

Target5-hydroxytryptamine receptor 1A(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525279(US11173137, Compound FA26 | US11173137, Compound ...)
Affinity DataKi: >1.00E+4nMAssay Description:Two exemplary compounds, FA44 and FA26, were screened against a panel of CNS receptors, transporters, and ion channels to examine specificity for CLC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

Target5-hydroxytryptamine receptor 1A(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525281(US11173137, Compound FA44 | US11173137, Compound A...)
Affinity DataKi: >1.00E+4nMAssay Description:Two exemplary compounds, FA44 and FA26, were screened against a panel of CNS receptors, transporters, and ion channels to examine specificity for CLC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetMetabotropic glutamate receptor 4(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525279(US11173137, Compound FA26 | US11173137, Compound ...)
Affinity DataKi: >1.00E+4nMAssay Description:Two exemplary compounds, FA44 and FA26, were screened against a panel of CNS receptors, transporters, and ion channels to examine specificity for CLC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetMetabotropic glutamate receptor 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525279(US11173137, Compound FA26 | US11173137, Compound ...)
Affinity DataKi: >1.00E+4nMAssay Description:Two exemplary compounds, FA44 and FA26, were screened against a panel of CNS receptors, transporters, and ion channels to examine specificity for CLC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetMetabotropic glutamate receptor 5(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525281(US11173137, Compound FA44 | US11173137, Compound A...)
Affinity DataKi: >1.00E+4nMAssay Description:Two exemplary compounds, FA44 and FA26, were screened against a panel of CNS receptors, transporters, and ion channels to examine specificity for CLC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetMetabotropic glutamate receptor 5(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525279(US11173137, Compound FA26 | US11173137, Compound ...)
Affinity DataKi: >1.00E+4nMAssay Description:Two exemplary compounds, FA44 and FA26, were screened against a panel of CNS receptors, transporters, and ion channels to examine specificity for CLC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M5(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525281(US11173137, Compound FA44 | US11173137, Compound A...)
Affinity DataKi: >1.00E+4nMAssay Description:Two exemplary compounds, FA44 and FA26, were screened against a panel of CNS receptors, transporters, and ion channels to examine specificity for CLC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M5(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525279(US11173137, Compound FA26 | US11173137, Compound ...)
Affinity DataKi: >1.00E+4nMAssay Description:Two exemplary compounds, FA44 and FA26, were screened against a panel of CNS receptors, transporters, and ion channels to examine specificity for CLC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetMetabotropic glutamate receptor 1(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525281(US11173137, Compound FA44 | US11173137, Compound A...)
Affinity DataKi: >1.00E+4nMAssay Description:Two exemplary compounds, FA44 and FA26, were screened against a panel of CNS receptors, transporters, and ion channels to examine specificity for CLC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetMetabotropic glutamate receptor 1(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525279(US11173137, Compound FA26 | US11173137, Compound ...)
Affinity DataKi: >1.00E+4nMAssay Description:Two exemplary compounds, FA44 and FA26, were screened against a panel of CNS receptors, transporters, and ion channels to examine specificity for CLC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetMetabotropic glutamate receptor 8(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525279(US11173137, Compound FA26 | US11173137, Compound ...)
Affinity DataKi: >1.00E+4nMAssay Description:Two exemplary compounds, FA44 and FA26, were screened against a panel of CNS receptors, transporters, and ion channels to examine specificity for CLC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetMetabotropic glutamate receptor 6(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525279(US11173137, Compound FA26 | US11173137, Compound ...)
Affinity DataKi: >1.00E+4nMAssay Description:Two exemplary compounds, FA44 and FA26, were screened against a panel of CNS receptors, transporters, and ion channels to examine specificity for CLC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525282(US11173137, Compound AK3-100A)
Affinity DataIC50: 1.26E+4nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525278(US11173137, Compound AK3-98A)
Affinity DataIC50: 1.37E+4nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525314(US11173137, Compound MCFA)
Affinity DataIC50: 1.39E+4nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525311(US11173137, Compound EEGI-056)
Affinity DataIC50: 1.58E+4nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525300(US11173137, Compound AK3-239)
Affinity DataIC50: 1.79E+4nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525258(US11173137, Compound AK2-209A)
Affinity DataIC50: 2.21E+4nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525272(US11173137, Compound AK2-289C)
Affinity DataIC50: 2.35E+4nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525267(US11173137, Compound AK2-288A)
Affinity DataIC50: 2.47E+4nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525274(US11173137, Compound AK3-89)
Affinity DataIC50: 3.34E+4nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525265(US11173137, Compound AK2-270A)
Affinity DataIC50: 3.57E+4nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525268(US11173137, Compound AK2-288B)
Affinity DataIC50: 3.79E+4nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525288(US11173137, Compound AK3-107B)
Affinity DataIC50: 4.20E+4nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525293(US11173137, Compound AK3-124)
Affinity DataIC50: 4.24E+4nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

TargetChloride channel protein 2(Human)
The Leland Stanford Junior University

US Patent
LigandPNGBDBM525286(US11173137, Compound AK3-103B)
Affinity DataIC50: 4.88E+4nMAssay Description:CLC-2 activity using cell-free assays, e.g., binding assays; with purified enzymes.More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
US Patent

Displayed 1 to 50 (of 85 total ) | Next | Last >>
Jump to: